Lotfi Yelles Chaouche
Directeur/Membre du Conseil chez Apaxen SA
Profil
Lotfi Yelles Chaouche currently works at Apaxen SA, as Director from 2019, Inhatarget Therapeutics, as Director, NeuVasQ Biotechnologies SA, as Director, Gepeceron SARL, as Director, and Theodorus Investment Funds, as Partner from 2017.
Mr. Yelles Chaouche also formerly worked at TheraVet SA, as Chairman in 2021 and ChromaCure SA, as Director.
Mr. Yelles Chaouche received his graduate degree from Institut Supérieur de l'Aéronautique et de l'Espace.
Postes actifs de Lotfi Yelles Chaouche
| Sociétés | Poste | Début |
|---|---|---|
Theodorus Investment Funds
 Theodorus Investment Funds Investment ManagersFinance Theodorus Investment Funds is a venture capital firm founded in 2003. The firm headquartered in Brussels, Belgium. | Private Equity Investor | 01/09/2017 |
Inhatarget Therapeutics
 Inhatarget Therapeutics Pharmaceuticals: MajorHealth Technology Inhatarget Therapeutics is a Belgian company that is developing targeted inhalation formulations to improve treatment for severe respiratory diseases, with a first focus on lung cancer. The company is based in Brussels, Belgium. The company is currently conducting clinical trials in 5 hospitals. The company's main objective is to create an inhaled chemotherapy for the treatment of lung cancer. | Directeur/Membre du Conseil | - |
Apaxen SA
 Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | Directeur/Membre du Conseil | 29/07/2019 |
NeuVasQ Biotechnologies SA
 NeuVasQ Biotechnologies SA Pharmaceuticals: MajorHealth Technology NeuVasQ Biotechnologies SA develops pharmaceutical products to treat neurological disorders by repairing neurovascular function. The company is based in Gosselies, Belgium. The Belgian company was founded in 2021 by Benoit Vanhollebeke. | Directeur/Membre du Conseil | - |
| Gepeceron SARL | Directeur/Membre du Conseil | - |
Anciens postes connus de Lotfi Yelles Chaouche
| Sociétés | Poste | Fin |
|---|---|---|
| THERAVET SA | Président | 20/12/2021 |
ChromaCure SA
 ChromaCure SA Pharmaceuticals: MajorHealth Technology ChromaCure SA develops therapeutic molecules to fight against cancer. The company is based in Charleroi, Belgium. The Belgian company was founded in 2018 by Cedric Blanpain, who has been the CEO since 2018. | Directeur/Membre du Conseil | - |
Formation de Lotfi Yelles Chaouche
| Institut Supérieur de l'Aéronautique et de l'Espace | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| THERAVET SA | Commercial Services |
| Entreprise privées | 6 |
|---|---|
Theodorus Investment Funds
Theodorus Investment Funds Investment ManagersFinance Theodorus Investment Funds is a venture capital firm founded in 2003. The firm headquartered in Brussels, Belgium. | Finance |
ChromaCure SA
ChromaCure SA Pharmaceuticals: MajorHealth Technology ChromaCure SA develops therapeutic molecules to fight against cancer. The company is based in Charleroi, Belgium. The Belgian company was founded in 2018 by Cedric Blanpain, who has been the CEO since 2018. | Health Technology |
Inhatarget Therapeutics
Inhatarget Therapeutics Pharmaceuticals: MajorHealth Technology Inhatarget Therapeutics is a Belgian company that is developing targeted inhalation formulations to improve treatment for severe respiratory diseases, with a first focus on lung cancer. The company is based in Brussels, Belgium. The company is currently conducting clinical trials in 5 hospitals. The company's main objective is to create an inhaled chemotherapy for the treatment of lung cancer. | Health Technology |
Apaxen SA
Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | Health Technology |
NeuVasQ Biotechnologies SA
NeuVasQ Biotechnologies SA Pharmaceuticals: MajorHealth Technology NeuVasQ Biotechnologies SA develops pharmaceutical products to treat neurological disorders by repairing neurovascular function. The company is based in Gosselies, Belgium. The Belgian company was founded in 2021 by Benoit Vanhollebeke. | Health Technology |
| Gepeceron SARL |
